BofA analyst Tazeen Ahmad upgraded Annexon to Buy from Neutral with a price target of $6, up from $4, after the company reported it has gained alignment with the U.S. Food and Drug Administration on a Phase 3 registration program for ANX007 for the treatment of patients with geographic atrophy, or GA. The firm thinks the news removes an overhang on the stock as it clarifies a key question on the path forward for GA and it also sees additional “meaningful catalysts” in 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ANNX:
- Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
- Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
- Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference